CN116056703A - 心房功能障碍的治疗 - Google Patents

心房功能障碍的治疗 Download PDF

Info

Publication number
CN116056703A
CN116056703A CN202180056887.4A CN202180056887A CN116056703A CN 116056703 A CN116056703 A CN 116056703A CN 202180056887 A CN202180056887 A CN 202180056887A CN 116056703 A CN116056703 A CN 116056703A
Authority
CN
China
Prior art keywords
patient
compound
atrial
optionally
atrial fibrillation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180056887.4A
Other languages
English (en)
Chinese (zh)
Inventor
J·F·坦比
J·M·埃德尔伯格
G·H·T·库里奥
C·L·凯莉
杨春
M·P·亨泽
C·L·德里奥
R·L·安德森
M·P·苏曼迪亚
J·甘舟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Myokardia Inc
Original Assignee
Myokardia Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Myokardia Inc filed Critical Myokardia Inc
Publication of CN116056703A publication Critical patent/CN116056703A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN202180056887.4A 2020-06-15 2021-06-14 心房功能障碍的治疗 Pending CN116056703A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063039438P 2020-06-15 2020-06-15
US63/039,438 2020-06-15
US202063042512P 2020-06-22 2020-06-22
US63/042,512 2020-06-22
PCT/US2021/037230 WO2021257456A1 (en) 2020-06-15 2021-06-14 Treatment of atrial dysfunction

Publications (1)

Publication Number Publication Date
CN116056703A true CN116056703A (zh) 2023-05-02

Family

ID=76845320

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180056887.4A Pending CN116056703A (zh) 2020-06-15 2021-06-14 心房功能障碍的治疗

Country Status (13)

Country Link
US (1) US20230233545A1 (cg-RX-API-DMAC7.html)
EP (1) EP4164644A1 (cg-RX-API-DMAC7.html)
JP (2) JP7832128B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230024977A (cg-RX-API-DMAC7.html)
CN (1) CN116056703A (cg-RX-API-DMAC7.html)
AU (1) AU2021293817A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022025551A2 (cg-RX-API-DMAC7.html)
CA (1) CA3180943A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022003548A1 (cg-RX-API-DMAC7.html)
IL (1) IL298885A (cg-RX-API-DMAC7.html)
MX (1) MX2022015488A (cg-RX-API-DMAC7.html)
TW (1) TW202214241A (cg-RX-API-DMAC7.html)
WO (1) WO2021257456A1 (cg-RX-API-DMAC7.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117379683A (zh) * 2023-12-12 2024-01-12 苏州晟智医疗科技有限公司 反搏辅助装置、计算设备、存储介质及反搏系统
CN118304374A (zh) * 2024-04-01 2024-07-09 山东省中医药研究院附属医院 一种组合物在制备治疗心动过速和/或瓣膜反流药物中的应用

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11759640B2 (en) * 2022-01-07 2023-09-19 Xyra, Llc Methods for reducing the risk of strokes by pharmacotherapy to reduce the number and duration of atrial fibrillations
CN116082326B (zh) * 2022-12-16 2024-12-27 药康众拓(江苏)医药科技有限公司北京分公司 一种氘代吡唑磺酰甲基-哌啶异噁唑脲类化合物及其用途
CN119157623A (zh) * 2023-12-12 2024-12-20 成都迈格因科技有限公司 一种经导管心脏射频消融的蒸汽爆破安全预警和控制系统

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201705928XA (en) * 2015-01-22 2017-08-30 Myokardia Inc 4-methylsulfonyl-substituted piperidine urea compounds for the treatment of dilated cardiomyopathy (dcm)
US10758525B2 (en) * 2015-01-22 2020-09-01 MyoKardia, Inc. 4-methylsulfonyl-substituted piperidine urea compounds
CA3060702A1 (en) * 2017-05-10 2018-11-15 Incarda Therapeutics, Inc. Unit doses, aerosols, kits, and methods for treating heart conditions by pulmonary administration
JP2020526483A (ja) * 2017-06-30 2020-08-31 アムジエン・インコーポレーテツド 心筋節活性化剤で心不全を治療する方法
SG11202112723PA (en) * 2019-05-19 2021-12-30 Myokardia Inc Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117379683A (zh) * 2023-12-12 2024-01-12 苏州晟智医疗科技有限公司 反搏辅助装置、计算设备、存储介质及反搏系统
CN117379683B (zh) * 2023-12-12 2024-02-27 苏州晟智医疗科技有限公司 反搏辅助装置、计算设备、存储介质及反搏系统
CN118304374A (zh) * 2024-04-01 2024-07-09 山东省中医药研究院附属医院 一种组合物在制备治疗心动过速和/或瓣膜反流药物中的应用

Also Published As

Publication number Publication date
AU2021293817A1 (en) 2023-01-19
JP2026048841A (ja) 2026-03-17
WO2021257456A1 (en) 2021-12-23
JP7832128B2 (ja) 2026-03-17
TW202214241A (zh) 2022-04-16
EP4164644A1 (en) 2023-04-19
KR20230024977A (ko) 2023-02-21
US20230233545A1 (en) 2023-07-27
BR112022025551A2 (pt) 2023-03-07
CL2022003548A1 (es) 2023-06-09
MX2022015488A (es) 2023-03-21
IL298885A (en) 2023-02-01
CA3180943A1 (en) 2021-12-23
JP2023529502A (ja) 2023-07-10

Similar Documents

Publication Publication Date Title
JP7832128B2 (ja) 心房機能不全の治療
US12616697B2 (en) Methods of treatment with myosin modulator
TWI874399B (zh) 心縮功能障礙之治療
Whelton et al. Acc/aha/aapa/abc/acpm/ags/APhA/ASH/ASPC/nma/pcna guideline for the prevention, Detection, evaluation, and management of high blood pressure in adults: a Report of the American College of Cardiology/American heart Association. Task force on clinical practice guidelines//J. Am. Coll. Cardiol.-2017.-Nov 13
Smolensky et al. Chronopharmacology and chronotherapy of cardiovascular medications: relevance to prevention and treatment of coronary heart disease
CA3223211A1 (en) Methods of using aldosterone synthase inhibitors
Aten et al. Dressler syndrome: not just a relic of the past
WO2024097284A1 (en) Mavacamten and derivatives thereof for use in treating atrial dysfunction
HK40091633A (en) Treatment of atrial dysfunction
US20250325531A1 (en) Treatment of systolic dysfunction
HK40061292A (en) Treatment of systolic dysfunction and heart failure with reduced ejection fraction with the compound(r)-4-(1-((3-(difluoromethyl)-1-methyl-1h-pyrazol-4-yl)sulfonyl)-1-fluoroethyl)-n-(isoxazol-3-yl)piperidine-1-carboxamide
BRUCE in the evaluation and monitoring of patients with
WO2025128432A1 (en) Istaroxime and metabolite derivatives thereof for reducing the risk of acute myocardial arrhythmia
O’Donnell et al. Cardiovascular Complications of Minoxidil Toxicosis in Two Dogs
HK40077232A (en) Methods of treatment with myosin modulator
Park et al. Pentoxifylline therapy: a new adjunct in the treatment of pulmonary hypertension?
Kateryna et al. GENDER SPECIFIC DIFFERENCES IN THE EFFECTS OF ANTIHYPERTENSIVE THERAPY ON ARTERIAL HEMODYNAMIC, ARTERIAL WALL STIFFNESS AND STRUCTURE-FUNCTIONAL CONDITION OF THE HEART IN PATIENTS OVER 65 YEARS OLD WITH UNCOMPLICATED ARTERIAL HYPERTENSION
Gallagher et al. Support of Cardiovascular Function

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40091633

Country of ref document: HK